Skip to main content

FSHD

2
Pipeline Programs
6
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Avidity Biosciences
Avidity BiosciencesCA - San Diego
3 programs
1
1
AOC 1020Phase 22 trials
AOC 1020Phase 1/21 trial
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A1 trial
Active Trials
NCT04635891Recruiting450Est. Jan 2028
NCT05747924Completed90Est. Mar 2026
NCT07038200Recruiting200Est. Jul 2028
+1 more trials
Dyne Therapeutics
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A
AMRA Medical
AMRA MedicalSweden - Linköping
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A
Genentech
GenentechCA - Oceanside
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A
Novartis
NovartisBASEL, Switzerland
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A
Sandoz
SandozAustria - Kundl
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Avidity BiosciencesAOC 1020
Avidity BiosciencesAOC 1020
Avidity BiosciencesAOC 1020
Avidity BiosciencesMotor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Clinical Trials (4)

Total enrollment: 824 patients across 4 trials

NCT07038200Avidity BiosciencesAOC 1020

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Start: Jun 2025Est. completion: Jul 2028200 patients
Phase 3Recruiting
NCT06547216Avidity BiosciencesAOC 1020

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: Jul 2024Est. completion: Jun 203084 patients
Phase 2Active Not Recruiting
NCT05747924Avidity BiosciencesAOC 1020

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: Apr 2023Est. completion: Mar 202690 patients
Phase 1/2Completed
NCT04635891Avidity BiosciencesMotor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Start: Dec 2020Est. completion: Jan 2028450 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 824 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FSHD | Pipeline & Competitive Landscape | Formulate